Attorney Docket P1989R1

**PATENT** 

EV 351932698 US: Express Mail Number

October 30, 2003: Date of Deposit

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Mail Stop PATENT APPLICATION Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450



# NON-PROVISIONAL APPLICATION TRANSMITTAL UNDER 37 CFR 1.53(b)

Transmitted herewith for filing is a non-provisional patent application:

Inventor(s) (or Application "Identifier"):				
	Charles P. Semba, Palo Alto, California			
Title:	PLASMINOGEN ACTIVATOR VARIANT FORMULATIONS			
1.	Type of Application			
[]	This application is for an original, non-provisional application.			
[X ]	This is a non-provisional application claiming priority to provisional application no. 60/426,616 , filed November 14, 2002 , the entire disclosure of which is hereby incorporated by reference.			
[]	This is a [] continuation-in-part [] continuation [] divisional application claiming priority to application Serial Number, filed, the entire disclosure of which is hereby incorporated by reference.			
2.	Papers Enclosed Which Are Required For Filing Date Under 37 CFR 1.53(b)  (Non-provisional)  40 pages of specification pages of claims 1 page(s) of abstract 0 sheet(s) of drawings [] formal [] informal			
3.	Declaration or Oath			
	(for new and CIP applications; also for Cont./Div. where inventor(s) are being added)  X An executed declaration of the inventor(s) [] is enclosed [X] will follow.			
	(for Cont./Div. where inventorship is the same or inventor(s) being deleted)  A copy of the executed declaration/oath filed in the prior application is enclosed			

(37	CFR	1.63	(d)).
-----	-----	------	-------

(for Cont./Div. where inventor(s) being deleted)

A signed statement is attached deleting inventor(s) named in the prior application (see 37 CFR 1.63(d)(2) and 1.33(b)).

# 4. Assignment

(for new and	CIP ap	plications)
--------------	--------	-------------

X An Assignment of the invention to GENENTECH, INC. [] is enclosed with attached Recordation Form Cover Sheet [X] will follow.

(for cont./div.)

The prior application is assigned of record to Genentech, Inc.

## 5. Amendments (for continuation and divisional applications)

 Cancel in this application original claims _	$\_$ of the prior application before calculating the filir	ηg
fee. (At least one original independent c	claim must be retained for filing purposes.)	

A preliminary amendment is enclosed. (Claims added by this amendment have been properly numbered consecutively beginning with the number next following the highest numbered original claim in the prior application.)

# 6. Fee Calculation (37 CFR 1.16)

The fee has been calculated as follows:

CLAIMS FOR FEE CALCULATION						
Number Filed		Number Extra		Rate	Basic Fee 37 CFR 1.16(a)	
					\$770.00	
Total Claims	35	- 20=	15	X \$18.00	\$270.00	
Independent Claims	5	- 3=	2	X \$86.00	\$172.00	
Multiple dependent claim(s), if any + \$290.00				\$0.00		
Filing Fee Calculation				\$1,212.00		

#### 7. Method of Payment of Fees

The Commissioner is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$1,212.00. A duplicate copy of this transmittal is enclosed.

P1989R1 Page 3 of 3

#### 8. **Authorization to Charge Additional Fees**

The Commissioner is hereby authorized to charge any additional fees required under 37 CFR §1.16

	and 1.17, or credit overpayment to Deposit Account No. 07-0630. <u>A duplicate copy of this transmittal is enclosed</u> .				
9.	Additional Papers Enclosed				
	<ul> <li>Information Disclosure Statement (37 CFR §1.98) w/ PTO-1449 and citations</li> <li>Submission of "Sequence Listing", computer readable copy, certificate re: sequence listing, and/or amendment pertaining thereto for biological invention containing nucleotide and/or amino acid sequence.</li> </ul>				
	<ul><li>A new Power of Attorney or authorization of agent.</li><li>Other:</li></ul>				
10. applica	Maintenance of Copendency of Prior Application (for continuation and divisional ations)				
	[This item <b>must</b> be completed and the necessary papers filed in the prior application if the period so in the prior application has run]				
	A petition, fee and/or response has been filed to extend the term in the pending prior application until				
	A copy of the petition for extension of time in the <i>prior</i> application is attached.				
11.	Correspondence Address:				

#### 1

\_X\_ Address all future communications to:

> Attn: Janet E. Hasak Customer No: 09157

> > Respectfully submitted, GENENTECH, INC.

Date: October 30, 2003

Reg. No. 28,616

Telephone No. (650) 225-1896

**CUSTOMER NO: 09157** 

# NONPUBLICATION REQUEST UNDER 35 U.S.C. 122(b)(2)(B)(i)

First Named Inventor		Named Inventor	Charles P. Semba	
	Title	Plasminog Formulati	en Activator Variant ons	-
	Attorr	ey Docket Number	P1989R1	

I hereby certify that the invention disclosed in the attached application has not and will not be the subject of an application filed in another country, or under a multilateral agreement, that requires publication at eighteen months after filing.

I hereby request that the attached application not be published under 35 U.S.C. 122(b).

October 30, 2003

Date

650/225-1896 Janet E. Hasak

Telephone number Typed or printed name

This request must be signed in compliance with 37 CFR 1.33(b) and submitted with the application **upon filing**.

Applicant may rescind this nonpublication request at any time. If applicant rescinds a request that an application not be published under 35 U.S.C. 122(b), the application will be scheduled for publication at eighteen months from the earliest claimed filing date for which a benefit is claimed.

If applicant subsequently files an application directed to the invention disclosed in the attached application in another country, or under a multilateral international agreement, that requires publication of applications eighteen months after filing, the applicant **must** notify the United States Patent and Trademark Office of such filing within forty-five (45) days after the date of the filing of such foreign or international application. **Failure to do so will result in abandonment of this application (35 U.S.C. 122(b)(2)(B)(iii)).** 

This collection of information is required by 37 CFR 1.213(a). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 6 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.